Orphan Diseases… a new pharmaceutical strategy?

As the old “blockbuster” mentality  fades in the wake of relatively weak pipelines, increased emphasis on drug safety, slow sales growth, and the loss of patent protection on older blockbusters, it would appear that the orphan-disease niche (i.e., low...